ZA200607013B - Methods for reducing oxidative damage - Google Patents

Methods for reducing oxidative damage

Info

Publication number
ZA200607013B
ZA200607013B ZA2006/07013A ZA200607013A ZA200607013B ZA 200607013 B ZA200607013 B ZA 200607013B ZA 2006/07013 A ZA2006/07013 A ZA 2006/07013A ZA 200607013 A ZA200607013 A ZA 200607013A ZA 200607013 B ZA200607013 B ZA 200607013B
Authority
ZA
South Africa
Prior art keywords
methods
oxidative damage
reducing oxidative
reducing
damage
Prior art date
Application number
ZA2006/07013A
Other languages
English (en)
Inventor
Hazel H Szeto
Original Assignee
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Res Foundation Inc filed Critical Cornell Res Foundation Inc
Publication of ZA200607013B publication Critical patent/ZA200607013B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
ZA2006/07013A 2004-01-23 2006-08-22 Methods for reducing oxidative damage ZA200607013B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53884104P 2004-01-23 2004-01-23
PCT/US2005/002119 WO2005072295A2 (en) 2004-01-23 2005-01-21 Methods for reducing oxidative damage

Publications (1)

Publication Number Publication Date
ZA200607013B true ZA200607013B (en) 2008-01-08

Family

ID=34826019

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2006/07013A ZA200607013B (en) 2004-01-23 2006-08-22 Methods for reducing oxidative damage

Country Status (13)

Country Link
US (8) US7550439B2 (https=)
EP (1) EP1722807A4 (https=)
JP (1) JP4931604B2 (https=)
KR (1) KR101159254B1 (https=)
CN (1) CN1938042B (https=)
AU (1) AU2005208821B8 (https=)
BR (1) BRPI0507053A (https=)
CA (7) CA3024434A1 (https=)
IL (5) IL177030A (https=)
NZ (1) NZ549393A (https=)
RU (1) RU2376028C2 (https=)
WO (1) WO2005072295A2 (https=)
ZA (1) ZA200607013B (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1599216B9 (en) * 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
PL2604286T3 (pl) * 2003-05-01 2015-03-31 Cornell Res Foundation Inc Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US8822542B2 (en) 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
GB0517090D0 (en) * 2005-08-19 2005-09-28 Tcp Innovations Ltd ApoE mimetic agents
CN104788540B (zh) * 2005-09-16 2019-10-18 科内尔研究基金会 用于减少cd36表达的方法
AU2019257440B2 (en) * 2005-09-16 2021-12-16 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
AU2014203126B2 (en) * 2005-09-16 2016-03-10 Cornell Research Foundation, Inc. Methods for reducing cd36 expression
JP5236641B2 (ja) 2006-07-25 2013-07-17 ハフ イヤ インスティテュート 急性音響外傷の治療方法
EP2114427B1 (en) 2007-01-30 2014-06-25 New York University Peptides for treatment of conditions associated with nitric oxide
JP4461159B2 (ja) * 2007-06-14 2010-05-12 ヤマハファインテック株式会社 プリント基板の検査装置および検査方法
EP2712620A1 (en) * 2008-02-07 2014-04-02 Cornell University Methods for Preventing or Treating Insulin Resistance
EP3741381B1 (en) * 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
DE102008061044A1 (de) * 2008-12-11 2010-06-17 Henkel Ag & Co. Kgaa Zusammensetzung mit antioxidativ wirksamen Peptiden
US20100331265A1 (en) * 2009-03-20 2010-12-30 Tompkins Ronald G Methods for the prevention and treatment of burn injuries and secondary complications
WO2011008202A1 (en) * 2009-07-15 2011-01-20 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
WO2011019809A1 (en) * 2009-08-12 2011-02-17 Cornell University Methods for preventing or treating metabolic syndrome
ES2964555T3 (es) * 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
WO2011044044A1 (en) * 2009-10-05 2011-04-14 Cornell University Methods for the prevention or treatment of heart failure
EP3266462A1 (en) * 2009-12-31 2018-01-10 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
EP3090754A1 (en) * 2009-12-31 2016-11-09 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
CA2787331A1 (en) * 2010-01-25 2011-07-28 Hazel H. Szeto Aromatic-cationic peptides and uses of same
JP2013521231A (ja) * 2010-02-26 2013-06-10 ユニバーシティ オブ フロリダ リサーチ ファウンデーション インコーポレイテッド ミトコンドリア標的化抗酸化剤は機械的人工呼吸誘発性横隔膜機能障害および骨格筋萎縮を防止する
EP3375449A1 (en) 2010-03-15 2018-09-19 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
US20110245182A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
US20110245183A1 (en) * 2010-04-06 2011-10-06 Perricone Nicholas V Topical Uses of Szeto-Schiller Peptides
EP3290433A1 (en) * 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
HUP1000243A2 (en) 2010-05-06 2012-01-30 Avidin Kft 8-hidroxy-quinoline derivatives
EP2590664B1 (en) * 2010-07-09 2019-03-27 Stealth Peptides International, Inc. Methods for the prevention or treatment of no-reflow following ischemia/reperfusion injury
WO2012009171A2 (en) * 2010-07-15 2012-01-19 The Schepens Eye Research Institute, Inc. Compositions and methods of treatment of corneal endothelium disorders
MX349622B (es) 2010-09-08 2017-08-07 Halozyme Inc Metodos para evaluar e identificar o evolucionar proteinas terapeuticas condicionalmente activas.
US20120083452A1 (en) * 2010-09-30 2012-04-05 Perricone Nicholas V Topical Anesthetic Uses of Szeto-Schiller Peptides
ES2893825T3 (es) 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
CA2839408A1 (en) * 2011-06-14 2012-12-20 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
CN106913860A (zh) 2011-09-29 2017-07-04 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
HK1201443A1 (en) * 2011-10-17 2015-09-04 Cornell University Aromatic-cationic peptides and uses of same
CN104244964A (zh) * 2012-02-22 2014-12-24 康肽德生物医药技术有限公司 用于预防或治疗眼科病状的方法和组合物
CN104203262A (zh) * 2012-02-23 2014-12-10 康奈尔大学 芳香族阳离子肽及其用途
AU2013229786B2 (en) 2012-03-08 2017-06-22 Halozyme, Inc. Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
CN104271146A (zh) * 2012-03-30 2015-01-07 康肽德生物医药技术有限公司 用于预防和治疗神经病的方法和组合物
US9687519B2 (en) 2013-03-01 2017-06-27 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
ES2755134T3 (es) 2013-03-01 2020-04-21 Stealth Biotherapeutics Corp Métodos para el tratamiento de enfermedad mitocondrial
WO2014210062A1 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods for the regulation of matrix metalloproteinase expression
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2015017861A1 (en) 2013-08-02 2015-02-05 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment of friedreich's ataxia
CA2925475A1 (en) * 2013-09-27 2015-04-02 Cornell University Use of aromatic-cationic peptides to treat cholesterol-induced mitochondrial dysfunction
EP3052115A4 (en) * 2013-09-30 2017-09-27 Cornell University Cardiolipin-targeted peptides inhibit beta-amyloid oligomer toxicity
JP2016539931A (ja) 2013-10-23 2016-12-22 株式会社カネカ テトラペプチド化合物及びその製造方法
JP2016540762A (ja) * 2013-12-02 2016-12-28 ステルス バイオセラピューティックス コープ 白斑の治療のための組成物及び方法
US20170007663A1 (en) * 2013-12-16 2017-01-12 Cornell University Methods and compositions for treating and preventing cognitive dysfunction
EP3071591B1 (en) * 2014-01-22 2021-05-05 Agency For Science, Technology And Research Antimicrobial peptidomimetics
US9314457B2 (en) 2014-06-19 2016-04-19 The University Of Utah Research Foundation Methods of treating and preventing vascular instability diseases
EP3160984B1 (en) 2014-06-25 2021-04-14 Flamma S.P.A. Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016001042A1 (en) 2014-06-30 2016-01-07 Flamma S.P.A. Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide
WO2016004093A2 (en) * 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
WO2016200364A1 (en) * 2015-06-08 2016-12-15 Stealth Peptides International, Inc. THERAPEUTIC COMPOSITIONS INCLUDING SkQ COMPOUNDS AND USES THEREOF
US11266716B2 (en) * 2015-10-22 2022-03-08 The Feinstein Institutes For Medical Research Use of dermcidin in sterile inflammatory conditions
CA3006698A1 (en) * 2015-11-30 2017-06-08 Peter Schiller Aromatic-cationic peptides conjugated to antioxidants and their use in treating complex regional pain syndrome
RU2613910C1 (ru) * 2015-12-08 2017-03-21 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ - ИМБП РАН) Способ определения тканевой гипоксии скелетных мышц и миокарда при гиподинамии
US20170224764A1 (en) * 2016-02-10 2017-08-10 Cornell University Therapeutic targeting of mitochondria to prevent osteoarthritis
CN107041946A (zh) * 2017-03-24 2017-08-15 南京大学 化合物ss‑31在制备治疗动脉粥样硬化及相关疾病药物或制剂上的应用
US20210206805A1 (en) * 2018-05-23 2021-07-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cardiac-specific targeting-peptide (ctp), compositions, and uses thereof
US20230190676A1 (en) * 2020-07-09 2023-06-22 Musc Foundation For Research Development Methods of protecting cells from insults
CN116390723B (zh) 2020-09-09 2024-12-31 社会利益网络公司 用于将生物素递送至线粒体的方法和组合物
CN117881411A (zh) 2021-06-01 2024-04-12 艾迪雅生物有限责任公司 用于眼部药物的延长释放药物递送系统和使用方法
CN114773433B (zh) * 2022-06-23 2022-09-06 北京肿瘤医院(北京大学肿瘤医院) 一种cd25靶向多肽、分子探针及应用
GB2630566A (en) * 2023-05-22 2024-12-04 Jaguar Land Rover Ltd Apparatus and method for controlling an actuator

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SG64368A1 (en) 1988-06-30 1999-04-27 Astra Ab Dermorphin analogs their methods of preparation pharmaceutical compositions and methods of therapeutic treatment using the same
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5118670A (en) * 1988-12-14 1992-06-02 Massachusetts Institute Of Technology Process and composition for increasing brain dopamine release
US5670617A (en) 1989-12-21 1997-09-23 Biogen Inc Nucleic acid conjugates of tat-derived transport polypeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
ATE255450T1 (de) * 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
DE69722258T2 (de) * 1996-10-07 2004-03-18 Eli Lilly And Co., Indianapolis Neue verbindungen nutlich als neuroschützende mittel
RU2115660C1 (ru) * 1997-01-28 1998-07-20 Институт биоорганической химии им.М.М.Шемякина и Ю.А.Овчинникова РАН Пептиды, обладающие антистрессорным, противосудорожным и нейропротекторным действием
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
US6417210B1 (en) * 1998-01-09 2002-07-09 Mor-Research Applications Ltd. Treatment of dyskinesias and Parkinson's disease with riluzole and levodopa
WO1999055321A1 (en) 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
DE60042338D1 (de) 1999-10-04 2009-07-16 Univ New Jersey Med TAR RNA bindende Peptide
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
US7498297B2 (en) 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
EP1339668A2 (en) 2000-11-28 2003-09-03 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
US6656971B2 (en) 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US20030077826A1 (en) 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
EP1599216B9 (en) 2003-02-04 2015-02-11 Cornell Research Foundation, Inc. Methods for preventing mitochondrial permeability transition
PL2604286T3 (pl) 2003-05-01 2015-03-31 Cornell Res Foundation Inc Sposoby i kompleksy nośnikowe do transportu cząsteczek do komórek
WO2005032481A2 (en) 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
CA3024434A1 (en) * 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
CN104788540B (zh) 2005-09-16 2019-10-18 科内尔研究基金会 用于减少cd36表达的方法

Also Published As

Publication number Publication date
AU2005208821A2 (en) 2005-08-11
CA2971928A1 (en) 2005-08-11
NZ549393A (en) 2009-07-31
CA2851972A1 (en) 2005-08-11
JP2007518818A (ja) 2007-07-12
AU2005208821A1 (en) 2005-08-11
US20190328821A1 (en) 2019-10-31
IL177030A (en) 2015-04-30
KR101159254B1 (ko) 2012-06-26
RU2006130431A (ru) 2008-02-27
CA2971928C (en) 2019-01-08
US20230149501A1 (en) 2023-05-18
CA2971929C (en) 2019-01-08
KR20070003872A (ko) 2007-01-05
WO2005072295A3 (en) 2005-09-29
US20100311664A1 (en) 2010-12-09
EP1722807A4 (en) 2010-09-15
CA2971929A1 (en) 2005-08-11
CN1938042A (zh) 2007-03-28
US20140349942A1 (en) 2014-11-27
IL256703A (en) 2018-03-29
IL237407A0 (en) 2015-04-30
BRPI0507053A (pt) 2007-06-12
CN1938042B (zh) 2010-06-02
CA2971931C (en) 2019-01-08
CA2851972C (en) 2015-06-23
US20210015887A1 (en) 2021-01-21
US7550439B2 (en) 2009-06-23
IL256703B (en) 2020-11-30
RU2376028C2 (ru) 2009-12-20
CA3024434A1 (en) 2005-08-11
US7781405B2 (en) 2010-08-24
US20160317604A1 (en) 2016-11-03
IL237408B (en) 2019-03-31
CA2554166A1 (en) 2005-08-11
US20070015711A1 (en) 2007-01-18
IL237407B (en) 2018-07-31
IL177030A0 (en) 2006-12-10
JP4931604B2 (ja) 2012-05-16
CA2887797C (en) 2017-09-26
AU2005208821B8 (en) 2010-10-14
US9950026B2 (en) 2018-04-24
WO2005072295A2 (en) 2005-08-11
CA2971931A1 (en) 2005-08-11
HK1102289A1 (zh) 2007-11-16
IL237408A0 (en) 2015-04-30
CA2554166C (en) 2014-07-29
IL235772A (en) 2016-12-29
US20060084606A1 (en) 2006-04-20
AU2005208821B2 (en) 2010-09-30
CA2887797A1 (en) 2005-08-11
US9623069B2 (en) 2017-04-18
EP1722807A2 (en) 2006-11-22
US8618061B2 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
IL256703B (en) Methods to reduce damage from oxidation
IL180331A0 (en) 3-carbamoyl - 2 - pyridone derivative
IL183278A0 (en) Rod-coupling assemblies
ZA200802867B (en) Fap inhibitors
GB0420061D0 (en) Method
GB0402639D0 (en) Method
GB0410478D0 (en) Method
GB0419419D0 (en) Method
GB0418651D0 (en) Method
GB0415009D0 (en) Method
HU0400305D0 (en) Set for spine-fixture
GB0412672D0 (en) Method
GB0412659D0 (en) Method
GB0414787D0 (en) Method
GB0420815D0 (en) Method
GB0405751D0 (en) Method
GB0419405D0 (en) Method
TWI315261B (en) Method for transferring-printing
GB0415081D0 (en) Method
GB0413714D0 (en) Method
GB0422354D0 (en) Procedure for reducing storm damage
ZA200500148B (en) Method for nano-sizing
ZA200704062B (en) Rod-coupling assemblies
GB0405597D0 (en) Method
GB0404931D0 (en) Method